The increase in net sales was driven by increases in the European and Asian Pacific markets, which grew 17 percent and 19 percent respectively. The American market was flat during this quarter. A previously announced voluntary suspension of the marketing and distribution of the Durom Acetabular Component in the United States made an impact on the company’s finances during the second quarter, costing $50 million for known and anticipated worldwide claims.
Despite the flat sales in the U.S., the company’s net sales were still carried by the American market. Net sales in the American reconstructive market was $449 million, which was a 2 percent decrease from last year. The U.S. knee market had net sales of $266 million, a 5 percent decrease, and hip market was $151 million, a 2 percent increase. The overall spine business fell by 2 percent compared to last year.
As the company’s sales slumped in these U.S. markets, the reconstructive, knee and hip product sales increased by percentages in the double-digits in both the European and Asian markets.
Read the release on Zimmer Holdings’ financial report.
Related Articles on Orthopedic Device Companies:
NuVasive Reports 2Q Revenue at $133M, 11.2% Increse
MiMedx Reports $1.9M 2Q Revenue, 6-Fold Increase
Stryker Reports $2.05B 2Q Net Sales, 12% Increase
